Today: 9 June 2026
Bitcoin Price Today: BTC Briefly Tops $68,000 as Iran Off-Ramp Talk Lifts Risk Mood
31 March 2026
2 mins read

Bitcoin Price Today: BTC Briefly Tops $68,000 as Iran Off-Ramp Talk Lifts Risk Mood

NEW YORK, March 31, 2026, 14:08 EDT

  • Bitcoin climbed roughly 1.2% to $67,557, having reached $68,370 earlier. Ether moved up 2.8% to $2,096.20.
  • U.S. spot bitcoin ETFs brought in $69.4 million on March 30, rebounding from the $225.5 million that moved out on March 27.
  • Strategy reported zero bitcoin buys during March 23-29, keeping its stash steady at 762,099 coins, each purchased for an average of $75,694.

Bitcoin edged higher on Tuesday, briefly climbing past $68,000 after news surfaced that U.S. President Donald Trump might consider ending military operations against Iran, even as the Strait of Hormuz remains mostly shut. The top cryptocurrency was recently up 1.2% at $67,557, rebounding from a session low of $66,001.

What’s notable here: bitcoin continues to trade in sync with equities and other risk assets, instead of showing classic safe-haven tendencies. Month- and quarter-end flows probably lifted prices, but with Brent holding near $115 and U.S. crude around $104, nerves across broader markets have hardly eased.

Fund flows chipped in to the rebound, too. U.S. spot bitcoin ETFs attracted $69.4 million in net inflows on March 30, according to Farside. That marked a turnaround from last week’s redemptions—March 27 alone saw $225.5 million head out the door.

The institutional setup looks murky. In a post Monday, Bitfinex pointed to a pickup in short-covering—traders closing out bearish positions—as the main fuel behind recent gains, not new money coming in. The firm also flagged ETF outflows as a sign that de-risking is underway.

Corporate buyers mostly stepped back as well. Strategy, in a March 30 filing, reported zero bitcoin purchases for the March 23-29 stretch and didn’t sell any shares via its share-sale program; the company’s stash stayed at 762,099 coins, locked in at an average of $75,694 apiece.

Equity investors keep a sharp eye on Strategy, largely due to its hefty bitcoin reserves. Right now, the company’s average purchase price is about 11% higher than where bitcoin traded on Tuesday. That gap underscores just how tough things get—even for big-name accumulators—when BTC trades south of $70,000.

Ethereum jumped 2.8% to $2,096.20, outpacing bitcoin’s gains for the session. Still, bitcoin trades far under its 2025 all-time high, a record topping $125,000.

Nexo’s Iliya Kalchev told Barron’s on Monday that cryptocurrencies are stuck in a “wait-and-see” phase. Scotiabank’s chief FX strategist, Shaun Osborne, didn’t mince words on the currency outlook: “There’s still a lot of uncertainty here about where we actually land on this.” Barron’s

That’s the risk here. A fresh jump in oil prices or a wider conflict could yank money out of crypto as fast as it flowed back in, with the same factors propping up the dollar. Bitfinex flagged the danger: tougher liquidity conditions and macro stress might still force a sharper correction.

The market’s got a bid, though not a strong one. Bitcoin has bounced above $67,500, pulling away from its session low. Still, with only tepid ETF inflows, uncertain corporate demand, and ongoing macro jitters tied to war, this move up looks more like a relief rally than a sign of real commitment.

Stock Market Today

  • SailPoint Q1 Earnings Beat Estimates Amid Revenue Growth
    June 9, 2026, 10:14 AM EDT. SailPoint, Inc. (SAIL) reported Q1 earnings of $0.05 per share, surpassing the Zacks Consensus Estimate of $0.04 by 17.65%. Revenue increased to $280.14 million, beating estimates by 1.41% and up from $230.47 million a year ago. Despite earnings surprises and revenue growth, SailPoint shares have declined 12.6% year-to-date against the S&P 500's 8.2% rise. The company holds a Zacks Rank #3 (Hold), indicating expected market-aligned performance. Consensus estimates forecast Q2 EPS of $0.08 on $310.79 million revenue and fiscal year EPS of $0.32 on $1.27 billion revenue. Industry trends in the Zacks Internet-Software sector will influence future stock performance. Investors await management's commentary for guidance on sustainability.

Latest articles

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

9 June 2026
Regentis Biomaterials shares dipped 2 cents to $1.28 premarket after the company announced European surgeon training for its GelrinC knee implant will begin in Q3, marking a key commercial step but leaving investors waiting for revenue proof as the stock trades far below its $8 IPO price.
IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

9 June 2026
IREN surged 8.9% to $59.19 and was quoted higher premarket after a bitcoin rebound and renewed focus on its pivot to AI cloud infrastructure, but the stock remains exposed to bitcoin swings, heavy spending, and risks tied to its new 800MW South Australia data center project and major contracts with Nvidia and Microsoft.
AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

9 June 2026
AT&T shares edged up to $22.58 pre-market after reaffirming 2026 guidance and a $45B+ shareholder return plan, providing a cash-flow marker as satellite broadband competition looms; the stock remains pressured by SpaceX risks flagged by Oppenheimer, with second-quarter free cash flow seen at $4.0–$4.5B.
GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

9 June 2026
GSK will buy Nuvalent for $10.6 billion in cash, paying a 40% premium, to boost its oncology pipeline ahead of looming HIV drug patent expiries; Nuvalent shares jumped 38.9% premarket while GSK fell 1.4%, with the deal expected to add to GSK sales and profit from 2027 but dilute earnings per share 2026-2028 if it closes in Q3, and final outcome depends on FDA approvals and regulatory clearance.
Dow Jones Today: Index Rebounds on Iran De-escalation Hopes, but Worst Month Since 2022 Still Looms
Previous Story

Dow Jones Today: Index Rebounds on Iran De-escalation Hopes, but Worst Month Since 2022 Still Looms

XRP Price Today: Why Fresh Inflows Still Can’t Stop the Slide Toward $1.30
Next Story

XRP Price Today: Why Fresh Inflows Still Can’t Stop the Slide Toward $1.30

Go toTop